Of 457 patients referred to a fibromyalgia clinic, 13 percent self-reported using cannabinoids, according to researcher Mary-Ann Fitzcharles of McGill University. A total of 80 percent were marijuana smokers, while 24 percent used prescription formulations and 3 percent used both, researchers reported in Arthritis Care & Research.
“The cannabinoid system has known modulatory effects on pain, inflammation, immune function and even joint damage,” said Ms. Fitzcharles. “It is therefore reasonable to question whether the effects of cannabinoid agonists, either natural or synthetic, may have relevance to the management of patients with pain conditions such as [fibromyalgia].”
Related Articles on Pain Management:
10 Pain Management Specialist Appointments
FDA Approves Lyrica for Neuropathic Pain Management
Lobbying Effort Aims to Tighten Control on Painkillers
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
